[1] Shen Y, Wu SD, Chen Y, et al. Alterations in gut microbiome and metabolomics in chronic hepatitis B infection-associated liver disease and their impact on peripheral immune response. Gut Microbes, 2023, 15(1):2155018. [2] Chen T, Chen G, Wang G, et al. Expert consensus on the diagnosis and treatment of end-stage liver disease complicated by infections. Hepatol Int, 2024, 18(3):817-832. [3] Antimicrobial Resistance Collaborators. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet, 2022, 399(10325):629-655. [4] Stracy M, Snitser O, Yelin I, et al. Minimizing treatment-induced emergence of antibiotic resistance in bacterial infections. Science, 2022, 375(6583):889-894. [5] 中华医学会肝病学分会.肝硬化诊治指南.实用肝脏病杂志,2019,22(6):770-786. [6] 尚红,王毓三,申子瑜,等.全国临床检验操作规程.第4版.北京:人民卫生出版社,2015:655-657. [7] Tapper EB, Parikh ND. Diagnosis and management of cirrhosis and its complications: A review. JAMA, 2023,329(18):1589-1602. [8] Garg P, Verma N, Angrup A, et al. Exploring the prevalence, predictors, and impact of bacterial infections to guide empiric antimicrobial decisions in cirrhosis (EPIC-AD). J Clin Exp Hepatol, 2024, 14(4):101352. [9] Piano S, Tonon M, Angeli P. Changes in the epidemiology and management of bacterial infections in cirrhosis. Clin Mol Hepatol, 2021, 27(3):437-445. [10] 李欣,张晓华,朱红玉,等.乙型肝炎肝硬化并发自发性细菌性腹膜炎病原菌及预后危险因素.中华医院感染学杂志,2024,34(13):1988-1991. [11] Li Y, Niu B, Liu J, et al. Bacterial infection adversely increases the risk of decompensation in patients with hepatitis B virus-related compensated cirrhosis: a retrospective study. BMC Infect Dis, 2024, 24(1):1446. [12] 陈燕,陆虎林,赵瑞红,等.肝硬化并发肠杆菌科细菌感染患者临床特点及预后相关因素.中国微生态学杂志,2021,33(12):1434-1440. [13] Feldman S, Russo A, Ceccarelli G, et al. Ceftazidime-avibactam for the treatment of carbapenem-resistant Klebsiella pneumoniae infections in patients with liver cirrhosis. J Clin Exp Hepatol, 2022, 12(5):1293-1300. [14] Miklasińska-Majdanik M. Mechanisms of resistance to macrolide antibiotics among staphylococcus aureus. Antibiotics (Basel), 2021, 10(11):1406. [15] Lima LM, Silva BNMD, Barbosa G, et al. β-lactam antibiotics: An overview from a medicinal chemistry perspective. Eur J Med Chem, 2020, 208:112829. [16] Bhatt S, Chatterjee S. Fluoroquinolone antibiotics: Occurrence, mode of action, resistance, environmental detection, andremediation - A comprehensive review. Environ Pollut, 2022, 315:120440. [17] Chen CW, Leimer N, Syroegin EA, et al. Structural insights into the mechanism of overcoming Erm-mediated resistance by macrolides acting together with hygromycin-A. Nat Commun, 2023, 14(1):4196. [18] Ma J, Song X, Li M, et al. Global spread of carbapenem-resistantEnterobacteriaceae: Epidemiological features, resistance mechanisms, detection and therapy. Microbiol Res, 2023, 266:127249. [19] Dalbeni A, Mantovani A, Zoncapè M, et al. The multi-drug resistant organisms infections decrease during the antimicrobial stewardship era in cirrhotic patients: An Italian cohort study. PLoS One, 2023, 18(2):e0281813. [20] Dalbeni A, Mantovani A, Zoncapè M, et al. The multi-drug resistant organisms infections decrease during the antimicrobial stewardship era in cirrhotic patients: An Italian cohort study. PLoS One, 2023, 18(2):e0281813. |